MARKET

NAMS

NAMS

NewAmsterdam Pharma Company N.V
NASDAQ
23.81
+0.23
+0.98%
After Hours: 23.81 0 0.00% 16:37 09/29 EDT
OPEN
23.52
PREV CLOSE
23.58
HIGH
24.54
LOW
23.26
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
42.21
52 WEEK LOW
21.02
MARKET CAP
2.85B
P/E (TTM)
-11.0878
1D
5D
1M
3M
1Y
5Y
1D
NewAmsterdam Pharma Begins Phase 2b Preclinical Alzheimer’s Trial
TipRanks · 8h ago
NewAmsterdam Pharma doses first participant in Phase 2b SPINOZA trial
TipRanks · 9h ago
NewAmsterdam Pharma Announces Dosing Of First Participant In SPINOZA, Phase 2b Clinical Trial Evaluating Obicetrapib In Individuals With Preclinical Alzheimer’s Disease
Benzinga · 9h ago
Weekly Report: what happened at NAMS last week (0921-0925)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and NewAmsterdam Pharma Company (NAMS)
TipRanks · 09/22 12:20
Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), NewAmsterdam Pharma Company (NAMS)
TipRanks · 09/22 12:10
EU Approval of Obicetrapib Products Strengthens NewAmsterdam
TipRanks · 09/21 21:22
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)
TipRanks · 09/21 16:10
More
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

Webull offers NewAmsterdam Pharma Company NV stock information, including NASDAQ: NAMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NAMS stock methods without spending real money on the virtual paper trading platform.